Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bettina Altmann

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Blood Advances|January 30, 2023
Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysisCatherine Thieblemont, Bettina Altmann, Fabian Frontzek, et al.
Hemasphere|December 8, 2022
First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA TrialFriederike Braulke, Florian Zettl, Marita Ziepert, et al.
The Lancet. Haematology|February 3, 2022
KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trialsDominic Kaddu-Mulindwa, Bettina Altmann, Sandra Robrecht, et al.
EMBO Molecular Medicine|June 19, 2016
USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphomaKatharina Engel, Martina Rudelius, Jolanta Slawska, et al.
Leukemia|August 16, 2024
Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaborationFabian Frontzek, Loïc Renaud, Ulrich Dührsen, et al.
Leukemia|May 9, 2020
Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trialGerald G Wulf, Bettina Altmann, Marita Ziepert, et al.
Blood Advances|December 8, 2025
Impact of Perforin 1 A91V germline background in patients with aggressive B-NHL treated with R-CHOPOnur Cetin, Igor Age Kos, Evi Regitz, et al.
Hemasphere|July 10, 2023
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER TrialGerhard Held, Lorenz Thurner, Viola Poeschel, et al.
Blood|January 29, 2021
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHLNorbert Schmitz, Lorenz Truemper, Krimo Bouabdallah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2024
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma)Olivier Tournilhac, Bettina Altmann, Birte Friedrichs, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Blood Advances|January 30, 2023
Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysisCatherine Thieblemont, Bettina Altmann, Fabian Frontzek, et al.
Hemasphere|December 8, 2022
First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA TrialFriederike Braulke, Florian Zettl, Marita Ziepert, et al.
The Lancet. Haematology|February 3, 2022
KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trialsDominic Kaddu-Mulindwa, Bettina Altmann, Sandra Robrecht, et al.
EMBO Molecular Medicine|June 19, 2016
USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphomaKatharina Engel, Martina Rudelius, Jolanta Slawska, et al.
Leukemia|August 16, 2024
Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaborationFabian Frontzek, Loïc Renaud, Ulrich Dührsen, et al.
Leukemia|May 9, 2020
Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trialGerald G Wulf, Bettina Altmann, Marita Ziepert, et al.
Blood Advances|December 8, 2025
Impact of Perforin 1 A91V germline background in patients with aggressive B-NHL treated with R-CHOPOnur Cetin, Igor Age Kos, Evi Regitz, et al.
Hemasphere|July 10, 2023
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER TrialGerhard Held, Lorenz Thurner, Viola Poeschel, et al.
Blood|January 29, 2021
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHLNorbert Schmitz, Lorenz Truemper, Krimo Bouabdallah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2024
Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma)Olivier Tournilhac, Bettina Altmann, Birte Friedrichs, et al.
Pageof 3